Last Updated on January 4, 2024 by The Health Master
The Central Drugs Standard Control Organisation (CDSCO) has issued a medical device alert on Baxter Healthcare’s Absorba Hemoperfusion Cartridge 300 C and Absorba 300 C, devices used in blood purification, due to the presence of particulate matter within the cartridge.
Baxter has informed the CDSCO that it “is issuing an urgent medical device recall for the Adsorba Hemoperfusion Cartridge 300 C and Adsorba 300 C due to the presence of particulate matter within the cartridge”.
If the particulate matter is not detected before use, the particles may reach the vascular system of the patient with potentially serious adverse health consequences, it added.
However, there have been no complaints or patient injuries associated with this issue, said the company in a regulatory filing.
The company has also released the batches/lots which were affected, with expiration dates ranging between February and October 2024.
Hemoperfusion is to complement existing blood purification technologies if the patient has taken life-threatening amounts of adsorbable drugs, or is in a deep coma and symptoms such as hypoventilation, hypotonia, hypothermia, and worsening of the clinical state despite conservative medical management, among others.
If the patient has taken drugs of which the amount, composition, and kind are unknown and the patient is deeply comatose, hemoperfusion can be considered.
The Adsorba has been proven a high degree of efficacy for drugs including barbiturates, organophosphates, bromo carbamide, paracetamol, ethchlorvynol, paraquat, meprobamate, and salicylate, among others.
The use of hemoperfusion as a supplementary treatment does not mean that other conventional methods of treatment should be omitted.
Measures such as gastric lovage, the establishment of a free airway and assisted respiration, controlled electrolyte and water balance and forced dieresis should be administered whenever indicated.
Furthermore, it might be necessary to monitor carefully the blood levels of vital substances or drugs which also could be adsorbed during the hemoperfusion treatment. Access to the bloodstream for hemoperfusion treatment can be obtained by normal hemodialysis methods.
The company said that any person who has used an affected Adsorba Hemoperfusion Cartridge 300C or Adsorba 300C may be affected.
CDSCO has said that it has not received any complaints from the market on this issue.
Baxter has asked customers to return the product directly to the company, if purchased directly from the company, by completing the customer reply form and sending it through email to Baxter.
If it has been purchased from a distributor, the company advises the customers to contact the distributor for return and credit.
CDSCO gives nod to make generic version of Pfizer’s Covid-19 pill
Norms for small Pharmaceutical firms may be eased
Govt invites applications to produce Vitamin B1
Drug recall: Magnesium Citrate Oral Solution recalled due to this reason
No extension in deadline for registration of Medical Devices
Drug recall: Sun Pharma, Glenmark recall products due to these manufacturing issues
Govt plans to reduce the prices of critical drugs on August 15
NMC directs State Medical Councils to take action against Quacks
FDA Haryana team raided, Codeine syrup recovered, FIR lodged
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
